Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-1 + Temozolomide in Recurrent High-Grade Gliomas
NCT07635173Phase 1Completed
- Sponsor
- Shenzhen Zhenxing Pharmaceutical Technology
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioma, sponsored by Shenzhen Zhenxing Pharmaceutical Technology. Primary endpoint: Dose-Limiting Toxicity at 4 weeks. Started Sep 2022; status: completed.
02
Conditions
glioma
Beyond the preview
Go deeper on NCT07635173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635173.